FDCNSEFDC Limited· PharmaceuticalsMediumNeutral
Announced Thu, 7 Aug · 14:14 IST

FDC Limited has informed the Exchange regarding Re-Appointment of Mr. Ashok A. Chandavarkar as Executive Director of the company w.e.f. March 01, 2026.

Management Changes View source PDF

FDC · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

FDC Limited's board, at its meeting on August 7, 2025, approved the re-appointment of Mr. Ashok A. Chandavarkar as Executive Director for a fresh 5-year term starting March 1, 2026 and ending February 28, 2031. The re-appointment is subject to shareholder approval at the upcoming Annual General Meeting. Mr. Chandavarkar has been with FDC since 1987 and was first appointed Executive Director in 1996, bringing over 38 years of pharmaceutical industry experience. The company also confirmed he is not debarred from holding a directorship by any SEBI order or other authority. He is related to several other directors on the board — brother of Mr. Mohan Chandavarkar, father of Mr. Ameya Chandavarkar, and uncle of Mr. Nandan and Ms. Nomita Chandavarkar.

Likely market impact

This is a continuity announcement — no change in leadership direction is expected. The re-appointment of a long-serving executive provides stability, but shareholder approval at the AGM will be a procedural checkpoint to watch.